TAKE16.78

TAKE Limited

· Pharma & Health
₹ CrorePeersVIMTALABSSUVENMcap ₹248 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)11.89
Receivable Days (DSO)39.191.471.47
Payable Days (DPO)260.27
Cash Conversion Cycle (days)-209.19
Working Capital Turnover-1.220.002.924.56
Asset Turnover0.740.001.501.50
Cash Conversion (CFO/Net Income)-0.08-0.44-0.38-0.38
CFO/EBITDA-0.692.192.162.16
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.